Jennifer Carter, MD
Hematology & Oncology · Great Falls, MTNPI 1891136644
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,861 of the $3,326 with a category attached, or 86.0%. It is spread thinly across 38 manufacturers, the largest accounting for just 10.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $914 and has fallen 90.0% since, to $91 in 2025.
Across 186 payments — averaging $17.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$341
- Merck$235
- Pfizer$188
- Takeda Pharmaceuticals U.S.A., Inc.$178
- Astellas Pharma US Inc$178
- Exelixis Inc.$174
- plus $2K from 32 others
What the payments were for
- Food & beverage$2,86186%
- Education$46514%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 24 | $341 |
| Merck | 14 | $235 |
| Pfizer | 18 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $178 |
| Astellas Pharma US Inc | 7 | $178 |
| Exelixis Inc. | 7 | $174 |
| AstraZeneca | 10 | $162 |
| Amgen | 10 | $161 |
| Seagen Inc. | 9 | $147 |
| Incyte Corporation | 8 | $146 |
| EMD Serono, Inc. | 1 | $130 |
| AbbVie | 6 | $112 |
| Sobi, Inc | 2 | $108 |
| Eisai Inc. | 7 | $106 |
| Sanofi | 6 | $101 |
| Johnson & Johnson | 6 | $93 |
| Genentech USA, Inc. | 5 | $84 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $74 |
| Daiichi Sankyo Inc. | 4 | $70 |
| Jazz Pharmaceuticals Inc. | 3 | $67 |
| Array Biopharma Inc | 2 | $52 |
| Bristol Myers Squibb | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Sumitomo Pharma America, Inc. | 2 | $36 |
| Karyopharm Therapeutics Inc. | 2 | $34 |
| Clovis Oncology, Inc. | 2 | $34 |
| AVEO Pharmaceuticals, Inc. | 2 | $34 |
| Blueprint Medicines Corporation | 2 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $29 |
| Boehringer Ingelheim | 1 | $19 |
| Coherus Oncology, Inc. | 1 | $17 |
| Pharmaessentia USA Corporation | 1 | $16 |
| Springworks Therapeutics, Inc. | 1 | $16 |
| Beigene USA, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Bayer | 1 | $14 |
| Myriad Genetic Laboratories, Inc. | 1 | $14 |
| Foundation Medicine, Inc. | 1 | $13 |
How this compares
$3,326 in reported general payments places this provider in the 70th percentile of 37 hematology & oncology providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 26 | $235,765 |
| BrukinsaZanubrutinib | 15 | $212,431 |
| Lenalidomide | 13 | $196,534 |
| Abiraterone Acetate | 22 | $45,862 |
| EliquisApixaban | 11 | $11,236 |
| Exemestane | 63 | $4,634 |
| Hydroxyurea | 45 | $538 |
| Tamoxifen Citrate | 16 | $342 |
| Letrozole | 24 | $297 |
| Prochlorperazine Maleate | 22 | $291 |
| Ondansetron OdtOndansetron | 13 | $252 |
| Dexamethasone | 12 | $207 |
| Anastrozole | 20 | $206 |
| Prednisone | 22 | $105 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta | $341 | $235,76526 claims |
| Beigene USA, Inc.Brukinsa | $15 | $212,43115 claims |
| PfizerEliquis | $188 | $11,23611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 37 hematology & oncology providers in Montana.
Other hematology & oncology in Great Falls
- Karl GuterGreat Falls$9K
- Thomas WarrGreat Falls$8K
- Patrick TangGreat Falls$7K
- Jessica KaaeGreat Falls$6K
- Grant HarrerGreat Falls$214
- Donald BerdeauxGreat Falls$35
- Patrick CobbBillings$21K
- Thomas WeinerHelena$14K
- Aaron FrankeSidney$11K
- Carolyn AksHavre$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.